In a research report released on Wednesday, Cowen analyst Ritu Baral initiated coverage on shares of Cytokinetics Inc. (NASDAQ:CYTK) with an Outperform rating and …
Cowen’s healthcare analyst Ritu Baral is weighing in with her thoughts on Intercept Pharmaceuticals (NASDAQ:ICPT), following the news that the company’s investigational product obeticholic acid (OCA) …
Cowen analyst Ritu Baral maintained an Outperform rating on Intercept Pharmaceuticals (NASDAQ:ICPT) with a price target of $420, as the company provided a clinical update …
Cowen analyst Ritu Baral reiterated an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) with a price target of $19, as the company announced data through Week 168 …
In a research report issued today, Cowen analyst Ritu Baral reiterated an Outperform rating on Amicus Therapeutics (NASDAQ:FOLD) with a $14 price target, following …
In a research report published today, Cowen analyst Ritu Baral maintained an Outperform rating on Cempra (NASDAQ:CEMP) and raised his price target to $35 …
In a research report released today, Cowen analyst Ritu Baral downgraded shares of Avanir Pharmaceuticals (NASDAQ:AVNR) from Outperform to Market Perform rating, and reduced her price …
Cowen analyst Ritu Baral maintained an Outperform rating on Avanir Pharmaceuticals (NASDAQ:AVNR) with a $20 price target, following the news that the company has entered …
Cowen analyst Ritu Baral reiterated an Outperform rating on Avanir Pharmaceuticals (NASDAQ:AVNR) with a $20 price target, following the news that the FDA has …
